Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

Stock Information for SI-BONE Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SI-BONE Inc.

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.